These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 32317009)
1. Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma. Raman L; Van der Linden M; Van der Eecken K; Vermaelen K; Demedts I; Surmont V; Himpe U; Dedeurwaerdere F; Ferdinande L; Lievens Y; Claes K; Menten B; Van Dorpe J Genome Med; 2020 Apr; 12(1):35. PubMed ID: 32317009 [TBL] [Abstract][Full Text] [Related]
2. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance. Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005 [TBL] [Abstract][Full Text] [Related]
3. Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma. Staaf J; Isaksson S; Karlsson A; Jönsson M; Johansson L; Jönsson P; Botling J; Micke P; Baldetorp B; Planck M Int J Cancer; 2013 May; 132(9):2020-31. PubMed ID: 23023297 [TBL] [Abstract][Full Text] [Related]
4. PCR-Free Shallow Whole Genome Sequencing for Chromosomal Copy Number Detection from Plasma of Cancer Patients Is an Efficient Alternative to the Conventional PCR-Based Approach. Beagan JJ; Drees EEE; Stathi P; Eijk PP; Meulenbroeks L; Kessler F; Middeldorp JM; Pegtel DM; Zijlstra JM; Sie D; Heideman DAM; Thunnissen E; Smit L; de Jong D; Mouliere F; Ylstra B; Roemer MGM; van Dijk E J Mol Diagn; 2021 Nov; 23(11):1553-1563. PubMed ID: 34454114 [TBL] [Abstract][Full Text] [Related]
5. Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer. Mao X; Zhang Z; Zheng X; Xie F; Duan F; Jiang L; Chuai S; Han-Zhang H; Han B; Sun J J Thorac Oncol; 2017 Apr; 12(4):663-672. PubMed ID: 28007624 [TBL] [Abstract][Full Text] [Related]
6. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC. Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431 [TBL] [Abstract][Full Text] [Related]
7. Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLC. Mohan S; Foy V; Ayub M; Leong HS; Schofield P; Sahoo S; Descamps T; Kilerci B; Smith NK; Carter M; Priest L; Zhou C; Carr TH; Miller C; Faivre-Finn C; Blackhall F; Rothwell DG; Dive C; Brady G J Thorac Oncol; 2020 Feb; 15(2):216-230. PubMed ID: 31629061 [TBL] [Abstract][Full Text] [Related]
8. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse. Almodovar K; Iams WT; Meador CB; Zhao Z; York S; Horn L; Yan Y; Hernandez J; Chen H; Shyr Y; Lim LP; Raymond CK; Lovly CM J Thorac Oncol; 2018 Jan; 13(1):112-123. PubMed ID: 28951314 [TBL] [Abstract][Full Text] [Related]
9. Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling. El Zarif T; Meador CB; Qiu X; Seo JH; Davidsohn MP; Savignano H; Lakshminarayanan G; McClure HM; Canniff J; Fortunato B; Li R; Banwait MK; Semaan K; Eid M; Long H; Hung YP; Mahadevan NR; Barbie DA; Oser MG; Piotrowska Z; Choueiri TK; Baca SC; Hata AN; Freedman ML; Berchuck JE Clin Cancer Res; 2024 Sep; 30(17):3798-3811. PubMed ID: 38912901 [TBL] [Abstract][Full Text] [Related]
10. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141 [TBL] [Abstract][Full Text] [Related]
11. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples. Van Paemel R; Vandeputte C; Raman L; Van Thorre J; Willems L; Van Dorpe J; Van Der Linden M; De Wilde J; De Koker A; Menten B; Devalck C; Vicha A; Grega M; Schleiermacher G; Iddir Y; Chicard M; van Zogchel L; Stutterheim J; Lak NSM; Tytgat GAM; Laureys G; Speleman F; De Wilde B; Lammens T; De Preter K; Van Roy N Eur J Cancer; 2022 Jan; 160():12-23. PubMed ID: 34794856 [TBL] [Abstract][Full Text] [Related]
12. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912 [TBL] [Abstract][Full Text] [Related]
13. Mutational spectrum of breast cancer by shallow whole-genome sequencing of cfDNA and tumor gene panel analysis. Ambriz-Barrera F; Rojas-Jiménez E; Díaz-Velásquez CE; De-La-Cruz-Montoya AH; Martínez-Gregorio H; Ruiz-De-La-Cruz M; Huertas A; Montealegre AL; Castro-Rojas C; Acosta G; Vaca-Paniagua F; Perdomo S PLoS One; 2024; 19(9):e0308176. PubMed ID: 39264897 [TBL] [Abstract][Full Text] [Related]
14. Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients. Martignano F; Munagala U; Crucitta S; Mingrino A; Semeraro R; Del Re M; Petrini I; Magi A; Conticello SG Mol Cancer; 2021 Feb; 20(1):32. PubMed ID: 33579306 [TBL] [Abstract][Full Text] [Related]
15. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases]. Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587 [No Abstract] [Full Text] [Related]
16. Read Count Patterns and Detection of Cancerous Copy Number Alterations in Plasma Cell-Free DNA Whole Exome Sequencing Data for Advanced Non-Small Cell Lung Cancer. Jang H; Choi CM; Lee SH; Lee S; Jeong MK Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361723 [TBL] [Abstract][Full Text] [Related]
17. Genomic Analysis of Circulating Tumor Cells at the Single-Cell Level. Lu S; Chang CJ; Guan Y; Szafer-Glusman E; Punnoose E; Do A; Suttmann B; Gagnon R; Rodriguez A; Landers M; Spoerke J; Lackner MR; Xiao W; Wang Y J Mol Diagn; 2020 Jun; 22(6):770-781. PubMed ID: 32247862 [TBL] [Abstract][Full Text] [Related]
18. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages. Guibert N; Pradines A; Favre G; Mazieres J Eur Respir Rev; 2020 Mar; 29(155):. PubMed ID: 32051167 [TBL] [Abstract][Full Text] [Related]
19. A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue. Sarkar FH; Valdivieso M; Borders J; Yao KL; Raval MM; Madan SK; Sreepathi P; Shimoyama R; Steiger Z; Visscher DW Diagn Mol Pathol; 1995 Dec; 4(4):266-73. PubMed ID: 8634783 [TBL] [Abstract][Full Text] [Related]
20. A combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer. Karlsson A; Cirenajwis H; Ericson-Lindquist K; Brunnström H; Reuterswärd C; Jönsson M; Ortiz-Villalón C; Hussein A; Bergman B; Vikström A; Monsef N; Branden E; Koyi H; de Petris L; Micke P; Patthey A; Behndig AF; Johansson M; Planck M; Staaf J Sci Rep; 2019 Mar; 9(1):5207. PubMed ID: 30914778 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]